A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Kestra Medical Technologies, Ltd. KMTS
Promising (early) broader-coverage candidate · Kestra Medical Technologies, Ltd.
On FrontierLab's discovery record since 2026-06-25 (8 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-04), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 59% |
|---|---|
| Gross margin | 51.4% |
| Gross profits / assets | 0.14 |
| Rule of 40 | -82.6 |
| Net margin | -141.6% |
| Cash runway (months) | 28.9 |
| PEG | — |
| Price / sales | 14.8 |
Quality checklist
- ✓ Revenue growth — 59% (pass ≥ 20%)
- ✓ Capital efficiency
- ~ Gross margin — 51.4% (pass ≥ 60%)
- ✓ Gross-margin trend — 10.9 (pass ≥ 2)
- ✓ Share dilution — 17.9%
Fundamentals — snapshot as of 2026-08-04
| Stage | Early |
|---|---|
| Share issuance (YoY) | 17.9% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-2.42 |
| Burn multiple | 0.9 |
| Gross-margin trend (pts) | 10.9 |
| Cash / assets | 0.55 |
| Net debt / EBITDA | — |
| Statements as of | Q4 FY2026 · filed 2026-07-14 |
Momentum context — a snapshot from 2026-08-04, not current
| Price at surface | $23.99 (as of 2026-08-04) |
|---|---|
| 52-week range | $14.1 – $30 |
| % off 52-wk high | -20% |
| RSI (14) | 53 |
| Relative volume | 0.9× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-08-04 (end-of-day). How grades are computed →